Dr. Klaus Paulini reports
AETERNA ZENTARIS ANNOUNCES POSITIVE RESULTS IN DOSE-FINDING PEDIATRIC STUDY OF MACIMORELIN
Aeterna Zentaris Inc. has released positive results for the first pediatric study of
as a growth hormone stimulation test for the evaluation of child onset growth hormone deficiency (CGHD).
This study, AEZS-130-P01 (study P01), was the first of two studies as agreed with the European Medicines Agency (EMA) in the company's pediatric investigation plan (PIP) for macimorelin. The goal of study P01 was to establish a dose that could both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD.
"The completion of study P01 is a noteworthy accomplishment in our pediatric development program for macimorelin. We are pleased with the final results of study P01, which demonstrated positive safety and tolerability data for use of macimorelin in child onset growth hormone deficiency. Furthermore, the PK/PD data observed are in the range as expected from the adult studies, which bolsters our confidence in the potential of macimorelin to address the significant market expansion opportunity. With the results from study P01 in hand, we have the necessary data as a promising basis for test validation study P02," said
Dr. Klaus Paulini, chief executive officer of Aeterna Zentaris.
- Positive results provide clinical framework to advance the company's pediatric investigation plan for macimorelin as a growth hormone deficiency diagnostic;
Pediatric PK/PD profile of macimorelin proved to be in the expected range and generally comparable with data in adults;
Planned safety and efficacy study P02 expected to commence in Q4 2020.
Study P01 was an international, multicentre study conducted in Hungary, Poland, Ukraine, Serbia, Belarus and Russia. In three cohorts comprising eight subjects each, macimorelin doses of 0.25-milligram-per-kilogram, 0.5-milligram-per-kilogram and one-milligram-per-kilogram body weight were investigated. In accordance with the study protocol, all enrolled patients completed four study visits after successful completion of the screening period. At visit 1 and visit 3, a provocative GH stimulation test was conducted according to the study sites' local practices. At visit 2, the macimorelin test was performed; following the oral administration of the macimorelin solution, blood samples were taken at predefined times for PK/PD assessment. Visit 4 was a safety follow-up visit at study end.
The completed study included 24 subjects aged four to 15 years. In the subjects who completed the study in accordance with the protocol, macimorelin demonstrated an excellent safety and tolerability profile. There were 88 adverse events (AE) reported in 23 subjects, none of which was assessed by the investigator as related to macimorelin. The majority of AEs (approximately 70 per cent) were expected side effects related to the hypoglycemia introduced by the insulin tolerance test. No significant changes in ECG parameters and safety laboratory values were noted in any of the three dosing cohorts.
The pharmacokinetic and pharmacodynamic profile of macimorelin proved to be in the expected range and in general comparable with data in adults.
"In cohort 3, all eight subjects presented a prominent exposure to macimorelin in their PK data, as well as growth hormone (GH) values above a threshold of 10 nanograms per millilitre, which is the upper cut-off point in children for the pediatric GHSTs," commented,
Dr. Nicola Ammer
, chief medical officer of Aeterna Zentaris. "Based on these data and in line with faster metabolism in children, a macimorelin dose of one milligram per kilogram was identified as the dose to be evaluated in the second study AEZS-130-P02 (study P02) on diagnostic efficacy and safety of macimorelin as GHD diagnostic in children."
Macimorelin, a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of macimorelin for the assessment of GHD.
In December, 2017, the United States Food and Drug Administration (FDA) granted Aeterna Zentaris marketing approval for macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen has been granted orphan drug designation by the FDA for diagnosis of AGHD. In January, 2019, the European Commission granted marketing authorization for macimorelin to Aeterna Zentaris for diagnosis of growth hormone deficiency in adults. In March, 2017, the pediatric committee of the EMA agreed to the company's PIP for macimorelin, a prerequisite for filing a marketing authorization application for any new medicinal product in Europe.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company's lead product, Macrilen, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen is currently marketed in the United States through a licence agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.